- $9.77bn
- $9.55bn
- $507.44m
U.S. RESEARCH ROUNDUP- Mastercard, Metagenomi, Ziff Davis
Brief: Glaukos Q1 Sales USD 85.6 Million Vs. IBES Estimate USD 79.6 Million
Glaukos Corp expected to post a loss of 57 cents a share - Earnings Preview
Brief: Glaukos Receives Permanent J-Code For Idose® TR (Travoprost Intracameral Implant)
Glaukos Corp reports results for the quarter ended in December - Earnings Summary
Brief: Glaukos Q4 Sales USD 82.4 Million Vs. IBES Estimate USD 79.1 Million
Glaukos Corp expected to post a loss of 55 cents a share - Earnings Preview
Brief: Glaukos Announces Preliminary, Unaudited Fourth Quarter And Full Year 2023 Net Sales
U.S. RESEARCH ROUNDUP-Boeing, Moody's, S&P Global
Glaukos jumps on FDA approval of eye implant
Brief: Glaukos Announces FDA Approval Of iDose TR
Glaukos Corp reports results for the quarter ended in September - Earnings Summary
Brief: Glaukos Q3 Sales USD 78 Million Vs. IBES Estimate USD 75.3 Million
Glaukos Corp expected to post a loss of 55 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Intuit, Rent the Runway, Tesla
Glaukos Corp reports results for the quarter ended in June - Earnings Summary
Brief: Glaukos Q2 Sales USD 80.4 Million Vs. IBES Estimate USD 74.7 Million
Glaukos Corp expected to post a loss of 55 cents a share - Earnings Preview
Brief: Glaukos Enters Into A Collaboration And Marketing Agreement With Radius Xr, Inc.